Assess whether a CMC change is a comparability or a new product (c46a8f)

Situation

CMC and Development Pathways work in a rare-disease team designing a pediatric plan now turns on a CMC change is because a payer demanding RWE the protocol cannot generate put 505(b)(2) literature-to-product bridge table in play. CMC change-control owner should say what 505(b)(2) literature-to-product bridge table proves.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose A CMC change is a comparability / A new product using 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• The population in 505(b)(2) literature-to-product bridge table is the one a payer demanding RWE the protocol cannot generate named, so A CMC change is a comparability follows for this CMC and Development Pathways file.
• The population in 505(b)(2) literature-to-product bridge table is adjacent only to a payer demanding RWE the protocol cannot generate; A new product is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a payer demanding RWE the protocol cannot generate before 505(b)(2) literature-to-product bridge table arrived; no new CMC and Development Pathways path.
• Provenance on 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate is broken; do not pick A CMC change is a comparability or A new product yet.

Analysis required

• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a payer demanding RWE the protocol cannot generate and write the one fact that would move a CMC change is for CMC change-control owner.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.